PolyLux, founded in 2016 and headquartered in Akron, Ohio, is an advanced materials company specializing in the development of light-switchable adhesive platforms. The company's core mission is to innovate medical adhesives to reduce complications such as Medical Adhesive Related Skin Injuries (MARSI). PolyLux's flagship product, AuraPeel, addresses the prevalent issue of skin damage caused by traditional medical adhesives, aiming to improve patient care and reduce healthcare costs.
Notable affiliates include a team of experts in materials science and healthcare. PolyLux has garnered attention from investors focused on medical technology innovations. The company has achieved significant milestones, including successful customer discovery indicating that MARSI affects 30% of hospital patients. By addressing a critical yet under-recognized problem in wound care, PolyLux is making a substantial impact in the medical field, enhancing patient outcomes and reducing treatment costs.
